US Stock Market Closed

Dashboard

Eli Lilly & Co. (LLY)

Current

- (-)

After Hours

Rating & Fair Value

Fair Value Premium lock
Institutional Holdings

H

Financial Strength

H

Sustainable Growth

B

Industry Comparison

H

Management & Equity

B

Analyst Opinion

S

Leverage & Liquidity

S

Fundamental Variables

H

Rating Performance

FV Performance

*There is a current rating on the stock that is included in these numbers based on its performance so far

About

Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. Its products include Forteo, Adrica, BAQSIMI, Basaglar and Glucagn. The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.

CEO

David A. Ricks

Employees

33,625

Industry

Diversified Biopharmaceuticals

Sector

Healthcare

Headquarters

Indianapolis

Exchange

New York Stock Exchange

Summary Stats

Market Cap

314B

Revenue

29.2B

Net Income

6.03B

EPS

$6.66

Price-to-Earnings

49.66

Price-to-Book

31.2

Debt-to-Equity

3.71

News

Analyst Ratings

Price targets projected by 15 analysts

High

$200.00

Average

$168.80

Low

$143.00

Ratings calculated by 18 analysts

Buy

10

Hold

8

Sell

0

Last Dividend

Amount

$0.98

Dividend Date

Frequency

quarterly

Dividend Yield

Earnings

Most Recent Earnings

Last Earnings for Q4 2022

Last Earnings

Above by $0.31

Actual

$2.09 +17.4%

Consensus

1.78

Report Date

Year Ago

2.49

Year Ago Change %

Down 16%

Actual vs Estimates

XX

xxx

Upcoming Estimates Unavailable

Expected EPS
-

-

Actual EPS
-

--

Competitors

star Favorites